D-Index & Metrics Best Publications
Svetomir N. Markovic

Svetomir N. Markovic

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 70 Citations 14,738 338 World Ranking 15829 National Ranking 8310

Overview

What is he best known for?

The fields of study he is best known for:

  • Cancer
  • Internal medicine
  • Chemotherapy

His primary areas of study are Internal medicine, Surgery, Oncology, Melanoma and Immunology. Svetomir N. Markovic works mostly in the field of Internal medicine, limiting it down to concerns involving Gastroenterology and, occasionally, Hazard ratio and Survival rate. His Oncology research includes elements of Meta-analysis, Survival analysis, Disease and Monoclonal.

His study in Melanoma is interdisciplinary in nature, drawing from both Differential diagnosis, Ipilimumab and Adjuvant therapy. His Immunology research is multidisciplinary, relying on both Cancer and Metastasis. Svetomir N. Markovic has researched Lymphocyte in several fields, including Stem cell and Lymphoma.

His most cited work include:

  • Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials (529 citations)
  • Malignant Melanoma in the 21st Century, Part 1: Epidemiology, Risk Factors, Screening, Prevention, and Diagnosis (290 citations)
  • Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. (259 citations)

What are the main themes of his work throughout his whole career to date?

Internal medicine, Oncology, Melanoma, Immunology and Surgery are his primary areas of study. His Internal medicine research integrates issues from Gastroenterology and Pathology. His work carried out in the field of Gastroenterology brings together such families of science as Hematopoietic stem cell transplantation, Area under the curve, Neutropenia and Hazard ratio, Confidence interval.

His Oncology study integrates concerns from other disciplines, such as Pembrolizumab, Metastatic melanoma, Clinical trial and Ipilimumab. His studies deal with areas such as Metastasis, Disease and Immunotherapy as well as Melanoma. The concepts of his Immunology study are interwoven with issues in Cancer and Cytotoxic T cell.

He most often published in these fields:

  • Internal medicine (52.49%)
  • Oncology (33.40%)
  • Melanoma (30.71%)

What were the highlights of his more recent work (between 2017-2021)?

  • Internal medicine (52.49%)
  • Melanoma (30.71%)
  • Cancer research (18.05%)

In recent papers he was focusing on the following fields of study:

The scientist’s investigation covers issues in Internal medicine, Melanoma, Cancer research, Cancer and Oncology. Many of his studies involve connections with topics such as Gastroenterology and Internal medicine. The various areas that Svetomir N. Markovic examines in his Melanoma study include Immunohistochemistry, Lesion, Metastasis and Disease.

His research in Cancer research intersects with topics in Bevacizumab and Immune checkpoint. The study incorporates disciplines such as Interquartile range, Antibody, Albumin and In vivo in addition to Cancer. His study on Oncology also encompasses disciplines like

  • Chemotherapy which is related to area like Targeted therapy,
  • Meta-analysis and Hazard ratio most often made with reference to Randomized controlled trial.

Between 2017 and 2021, his most popular works were:

  • Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis. (175 citations)
  • Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy. (80 citations)
  • Rheumatic Syndromes Associated With Immune Checkpoint Inhibitors: A Single-Center Cohort of Sixty-One Patients. (58 citations)

In his most recent research, the most cited papers focused on:

  • Cancer
  • Internal medicine
  • Chemotherapy

Svetomir N. Markovic focuses on Internal medicine, Melanoma, Immunotherapy, Oncology and Cancer research. His study in Adverse effect, Cohort, Meta-analysis, Pembrolizumab and Resiquimod is carried out as part of his studies in Internal medicine. His Melanoma research is multidisciplinary, incorporating elements of Chemokine, Immune system and Clinical trial, Phases of clinical research.

The Immunotherapy study combines topics in areas such as Lung cancer, Chemotherapy and Immunogenicity. Svetomir N. Markovic focuses mostly in the field of Oncology, narrowing it down to topics relating to Hazard ratio and, in certain cases, Randomized controlled trial. He has researched Cancer research in several fields, including Immune checkpoint, Cytotoxic T cell, CD40, T cell and Tumor necrosis factor receptor.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials

Edward L. Korn;Ping Yu Liu;Sandra J. Lee;Judith Anne W. Chapman.
Journal of Clinical Oncology (2008)

714 Citations

Malignant Melanoma in the 21st Century, Part 1: Epidemiology, Risk Factors, Screening, Prevention, and Diagnosis

Svetomir N. Markovic;Lori A. Erickson;Ravi D. Rao;Robert R. McWilliams.
Mayo Clinic Proceedings (2007)

610 Citations

Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma.

Luis F. Porrata;Morie A. Gertz;David J. Inwards;Mark R. Litzow.
Blood (2001)

392 Citations

Cancer and pregnancy: parallels in growth, invasion, and immune modulation and implications for cancer therapeutic agents.

Shernan G. Holtan;Douglas J. Creedon;Paul Haluska;Svetomir N. Markovic.
Mayo Clinic Proceedings (2009)

288 Citations

Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis.

Yucai Wang;Shouhao Zhou;Shouhao Zhou;Fang Yang;Xinyue Qi.
JAMA Oncology (2019)

285 Citations

Therapy for metastatic melanoma: the past, present, and future

Laura Finn;Svetomir N Markovic;Richard W Joseph.
BMC Medicine (2012)

257 Citations

B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders.

Ryan A. Wilcox;Andrew L. Feldman;David A. Wada;Zhi Zhang Yang.
Blood (2009)

214 Citations

Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma.

Stephen M. Ansell;Thomas E. Witzig;Paul J. Kurtin;Jeff A. Sloan.
Blood (2002)

212 Citations

Acquired C1 esterase inhibitor deficiency.

Svetomir N. Markovic;David J. Inwards;Evangelos A. Frigas;Robert P. Phyliky.
Annals of Internal Medicine (2000)

207 Citations

Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A.

Domingo G. Perez;Vera J. Suman;Tom R. Fitch;Thomas Amatruda.
Cancer (2009)

206 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Svetomir N. Markovic

Stephen M. Ansell

Stephen M. Ansell

Mayo Clinic

Publications: 74

John M. Kirkwood

John M. Kirkwood

University of Pittsburgh

Publications: 73

Paolo A. Ascierto

Paolo A. Ascierto

National Institutes of Health

Publications: 72

Dirk Schadendorf

Dirk Schadendorf

University of Duisburg-Essen

Publications: 56

Axel Hauschild

Axel Hauschild

Kiel University

Publications: 45

Reinhard Dummer

Reinhard Dummer

University of Zurich

Publications: 41

Morie A. Gertz

Morie A. Gertz

Mayo Clinic

Publications: 41

Georgina V. Long

Georgina V. Long

University of Sydney

Publications: 40

Alexander M.M. Eggermont

Alexander M.M. Eggermont

Institut Gustave Roussy

Publications: 39

Thomas E. Witzig

Thomas E. Witzig

Mayo Clinic

Publications: 38

Vernon K. Sondak

Vernon K. Sondak

University of South Florida

Publications: 38

Keith T. Flaherty

Keith T. Flaherty

Harvard University

Publications: 37

Caroline Robert

Caroline Robert

Institut Gustave Roussy

Publications: 37

Claus Garbe

Claus Garbe

University of Tübingen

Publications: 34

John F. Thompson

John F. Thompson

University of Sydney

Publications: 34

Haidong Dong

Haidong Dong

Mayo Clinic

Publications: 33

Something went wrong. Please try again later.